An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04514367|
Recruitment Status : Completed
First Posted : August 14, 2020
Last Update Posted : January 31, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Huntington Disease||Drug: ANX005||Phase 2|
The objective of this study is to evaluate the effects of intravenous ANX005 administered for up to 22 weeks in subjects with, or at risk for, manifest Huntington's Disease.
Subjects will receive induction dosing of ANX005 administered by IV infusion on Days 1 and 5 or 6, followed by maintenance dosing every 2 weeks through Week 22, with follow up visits on Weeks 24, 28, and 36.
All subjects will be contacted (in clinic visit or phone call) 6 months after study completion.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||28 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||ANX005 administered for up to 22 weeks|
|Masking:||None (Open Label)|
|Official Title:||A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease|
|Actual Study Start Date :||August 17, 2020|
|Actual Primary Completion Date :||January 28, 2022|
|Actual Study Completion Date :||January 28, 2022|
- Safety and tolerability of intravenous ANX005 administered for up to 22 weeks in subjects with, or at risk for, manifest Huntington's Disease [ Time Frame: Up to Week 36 ]As measured by incidence of TEAEs, SAEs, AEs related to ANX005, SAEs related to ANX005, Grade 3 or higher AEs, Grade 3 or higher AEs related to ANX005, AEs leading to study or treatment discontinuation.
- Pharmacokinetics (PK) of ANX005 [ Time Frame: Up to Week 36 ]As measured by ANX005 serum and cerebrospinal fluid concentrations
- Pharmacodynamics (PD) effects of ANX005 [ Time Frame: Up to Week 36 ]As measured by C1q, C4a, and NfL levels in blood and/or cerebrospinal fluid concentrations
- Exploratory effects of ANX005 on measures of efficacy [ Time Frame: Up to Week 36 ]As measured by Unified Huntington's Disease Rating Scale '99 (UHDRS)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Diagnosis of or at risk for Huntington's disease: Genetically confirmed disease by direct DNA testing, total CAG-Age Product (CAP) score > 400 and UHDRS independence score ≥ 80.
- Able to walk independently and self-sufficient in basic activities of daily living (e.g. eating, dressing, bathing).
- All HD concomitant medications stable.
- If female, must be postmenopausal (no menses for at least 2 years without an alternative medical cause), surgically sterilized (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or agree to use highly effective methods of contraception.
- Males with a woman of childbearing potential partner must agree to use highly effective methods of contraception.
- Previously vaccinated against encapsulated bacterial pathogens (Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae) or willing to undergo vaccination.
- Able to tolerate EEG and lumbar puncture (LP) procedures.
- Be at risk of suicide or self-harm within the preceding 12 months.
- Chorea and/or cognitive deficits severe enough to interfere with study assessments.
- Subjects with body weight > 150 kg.
- Clinically significant findings on the screening laboratory testing or physical examination that are not specific to HD and may interfere with the conduct of the study or the interpretation of the data or increase subject risk.
- Signs and symptoms of, or a diagnosis consistent with a chronic autoimmune disorder and/or an ANA titer ≥ 1:160.
- History of previous infusion reactions, sensitivities, allergic, or anaphylactic reactions to previous medications, environmental stimuli or other substances.
- Use of an experimental agent within 60 days or five half-lives prior to Screening or anytime over the duration of this study.
- Prior treatment with any monoclonal antibody.
- Presence of an implanted deep brain stimulation device.
- Any history of gene therapy, RNA or DNA targeted HD specific investigational agents such as antisense oligonucleotides, cell transplantation or any experimental brain surgery.
- Brain and spinal pathology that may interfere with cerebrospinal fluid homeostasis and circulation, increases intracranial pressure (implanted shunt or catheter), malformations or tumor.
- Contraindication to undergoing an LP.
- Hypersensitivity to any of the excipients in the ANX005 drug product.
- Clinically significant intercurrent illness, medical condition, or medical history (including neurological or mental illness, HIV, any active infection, including Hepatitis B or C) that would jeopardize the safety of the subject, limit participation, or compromise the interpretation of the data derived from the subject.
- Any known genetic deficiencies of the complement-cascade system.
- History of chronic oral or intravenous steroid use or immunosuppressant medication use.
- Hemoglobin, bilirubin, or lactate dehydrogenase (LDH) values that are outside normal limits and clinically significant or suggestive of hemolytic anemia.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04514367
|United States, Alabama|
|Annexon Investigational Site 02|
|Birmingham, Alabama, United States, 35294|
|United States, Colorado|
|Annexon Investigational Site 03|
|Englewood, Colorado, United States, 80113|
|United States, District of Columbia|
|Annexon Investigational Site 04|
|Washington, District of Columbia, United States, 20057|
|United States, North Carolina|
|Annexon Investigational Site 07|
|Durham, North Carolina, United States, 27710|
|United States, Ohio|
|Annexon Investigational Site 06|
|Cincinnati, Ohio, United States, 45221|
|United States, Washington|
|Annexon Investigational Site 08|
|Kirkland, Washington, United States, 98034|
|Study Director:||Benjamin Hoehn, MD||Annexon, Inc.|
|Responsible Party:||Annexon, Inc.|
|Other Study ID Numbers:||
|First Posted:||August 14, 2020 Key Record Dates|
|Last Update Posted:||January 31, 2023|
|Last Verified:||January 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Basal Ganglia Diseases
Central Nervous System Diseases
Nervous System Diseases
Heredodegenerative Disorders, Nervous System
Genetic Diseases, Inborn